At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 120 enrolled
Drug / intervention
Mitomycin cdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC
In Brief
A Phase 4 clinical trial evaluating Mitomycin c for Bladder Cancer. Completed, enrolled 120 participants across 1 site.
Detailed Summary
A randomized controlled trial aiming to investigate neoadjuvant, short-term intensive chemoresection with Mitomycin C compared to standard treatment with TURB and adjuvant intravesical instillation therapy in patients with recurrent non-muscle invasive bladder cancer (NMIBC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBladder Cancer
CountriesDenmark
Collaborators--
Timeline
Phase 4CompletedFinished
201820192020202120222023202420252026
Enrollment StartNov 2017
First PostedNov 2017
Primary CompletionJun 2019
Study CompletionDec 2025
TodayJul 2026
First PostedNov 21, 2017
Enrollment StartNov 1, 2017
Primary CompletionJun 11, 2019
Study CompletionDec 31, 2025
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.6 years ago
Interventions
Mitomycin cdrug
Neoadjuvant Mitomycin C